Top 10 Effects of Psychotropics in Dementia, What MyQA Audits Should Check
Psychotropics in dementia, why effects matter to quality assurance
In adult social care, psychotropic medicines are commonly used to manage distress, agitation, psychosis, sleep disturbance, and anxiety in people living with dementia. These medicines can sometimes be clinically appropriate, but they carry significant risks. For care homes, the quality assurance challenge is not only whether a drug was prescribed, but whether the ongoing use is lawful, proportionate, monitored, and regularly reviewed. This aligns directly with CQC expectations, the Mental Capacity Act, safe medicines management requirements, and good practice guidance on reducing over medication.
MyQA audits should connect the clinical risk to day to day practice. That means checking documentation quality, staff understanding, monitoring systems, PRN governance, incident learning, and whether non pharmacological approaches are in place and tried first. The effects below are common, high impact, and frequently missed in recording or escalation pathways.
Scope note Psychotropics can include antipsychotics, antidepressants, anxiolytics, hypnotics, mood stabilisers, and some anti epilepsy medicines used for behaviour. Effects vary by medicine, dose, and the person’s health. Always consider polypharmacy, frailty, renal impairment, and drug interactions.
Top 10 effects of psychotropics in dementia, what MyQA audits should check
1. Sedation, reduced alertness, and loss of function
What it looks like: Sleepiness, slowed responses, reduced engagement, new dependence with mobility or personal care, missed meals, and increased time in bed. In dementia, sedation can be mistaken for the condition worsening rather than a medicine effect.
Why it matters: Sedation increases risk of falls, pressure damage, dehydration, aspiration, and social withdrawal. It may also reduce capacity to participate in decisions and daily life, raising safeguarding and human rights concerns.
MyQA audit checks:
Confirm a clear, time limited indication for the medicine, linked to specific target symptoms. Check whether baseline function is recorded before starting or increasing doses. Look for structured monitoring, such as daily alertness notes, sleep charts where appropriate, and evidence that staff report changes to a prescriber promptly. Review whether the care plan supports activity and meaningful occupation rather than accepting sedation as the norm. Check whether medicine administration times are appropriate, for example hypnotics given at night rather than early evening unless justified.
2. Falls, unsteady gait, and fractures
What it looks like: New unsteadiness, postural hypotension, slow reaction time, and increased falls, often after initiation or dose changes. Benzodiazepines, antipsychotics, and some antidepressants are frequent contributors.
Why it matters: Falls can lead to fractures, hospital admission, delirium, loss of independence, and serious harm. Recurrent falls also indicate poor medicines optimisation and inadequate monitoring.
MyQA audit checks:
Cross reference incident reports with MAR records to identify temporal links with new prescriptions, PRN use, or dose increases. Check that a falls risk assessment is updated after any psychotropic change. Confirm orthostatic blood pressure checks when clinically indicated. Review whether post fall reviews include medicines as a contributing factor and whether actions were completed. Ensure physiotherapy, mobility aids, and footwear checks are documented as part of a multi factor plan, not only medication focused.
3. Anticholinergic burden and physical complications
What it looks like: Constipation, urinary retention, dry mouth, blurred vision, tachycardia, confusion, and worsening delirium. Some antipsychotics, antidepressants, and anti Parkinsonian drugs used to manage side effects can add to cumulative anticholinergic load.
Why it matters: Constipation and urinary retention can cause pain, agitation, reduced appetite, and hospital admission. Dry mouth and poor swallow increase aspiration risk. Anticholinergic burden is also linked to cognitive decline.
MyQA audit checks:
Check bowel charts, hydration monitoring, and constipation care plans, especially when psychotropics are prescribed. Confirm stool softeners or laxatives are used appropriately and reviewed, rather than added indefinitely. Look for bladder care monitoring, UTI differentiation from delirium, and clear escalation for urinary retention symptoms. Audit mouth care plans and whether staff record oral health concerns. Consider whether an anticholinergic burden review has been requested from pharmacy or prescriber when multiple medicines contribute.
4. Extrapyramidal symptoms and movement disorders
What it looks like: Tremor, rigidity, bradykinesia, shuffling gait, restlessness, dystonia, and tardive dyskinesia. These can appear as agitation or functional decline and may be missed in people with communication difficulties.
Why it matters: Movement disorders increase falls risk, distress, swallowing problems, and poor quality of life. Some effects can become long lasting if not identified early.
MyQA audit checks:
Check whether staff know early warning signs and whether observation notes mention new tremor, stiffness, facial movements, or pacing. Confirm that care plans include monitoring after initiation of antipsychotics and that prescriber reviews consider dose reduction or switching. Review whether PRN antipsychotic use is frequent, as repeated dosing increases risk. Look for referral evidence where appropriate, such as GP, community mental health team, or neurology input for persistent symptoms.
5. Increased risk of stroke and transient ischaemic attack
What it looks like: Sudden weakness, facial droop, speech changes, confusion, or loss of coordination. Antipsychotics in dementia are associated with increased cerebrovascular risk, particularly in people with existing risk factors.
Why it matters: This is a serious harm risk and often a key concern for families and regulators. It also requires clear risk benefit decision making and documented consent processes.
MyQA audit checks:
Confirm the prescribing rationale includes discussion of cerebrovascular risk and consideration of alternatives. Check that baseline risk factors are documented, such as previous stroke, atrial fibrillation, hypertension, diabetes, smoking history, and frailty. Audit whether best interests decisions and family involvement are recorded when capacity is lacking. Ensure staff training includes FAST recognition and escalation procedures. Verify that emergency response pathways are known and practiced, including when to call emergency services.
6. Cardiac effects, QT prolongation, and sudden collapse
What it looks like: Palpitations, dizziness, syncope, or unexplained collapse. Some antipsychotics and antidepressants can prolong QT interval, especially with electrolyte imbalance or interacting medicines.
Why it matters: Cardiac rhythm disturbances can be fatal. Risk increases with polypharmacy, dehydration, low potassium or magnesium, and existing heart disease.
MyQA audit checks:
Check whether prescribers requested ECG monitoring when indicated and whether results are filed and acted on. Review electrolyte monitoring where appropriate, especially if diuretics, vomiting, diarrhoea, or poor intake is present. Audit medicine interaction checks, including pharmacy reviews. Ensure care plans address hydration and nutrition, because these can indirectly reduce cardiac risk. Cross check any episodes of collapse with medicine timing, PRN administration, and recent dose changes.
7. Metabolic effects, weight change, and diabetes risk
What it looks like: Increased appetite, weight gain, raised blood glucose, lipid changes, or conversely weight loss due to sedation and reduced intake. Some antipsychotics are associated with significant metabolic change.
Why it matters: Metabolic deterioration increases infection risk, slows wound healing, and affects long term health outcomes. Weight change can also signal swallowing issues, depression, or adverse effects.
MyQA audit checks:
Check weight monitoring frequency and triggers for escalation. Confirm MUST assessments are completed and updated, and that food and fluid charts are used when indicated. Look for diabetes monitoring where relevant, including HbA1c checks through primary care and daily glucose monitoring if prescribed. Ensure care planning includes healthy diet support, activity, and review of sedating medicines that reduce mobility. Verify actions are recorded and followed up, not just measurements taken.
8. Paradoxical agitation, disinhibition, and worsening behaviour
What it looks like: Increased restlessness, irritability, aggression, impulsivity, or sleep disruption shortly after starting or increasing certain medicines, particularly benzodiazepines or some antidepressants.
Why it matters: If staff interpret this as the person needing more medication, a cycle of escalation can occur. This increases restraint risk, harms relationships, and can trigger safeguarding concerns.
MyQA audit checks:
Audit ABC charts or behaviour monitoring tools for patterns around medicine changes. Check whether PRN use is clearly justified with objective description of distress and whether non pharmacological interventions are documented first. Review whether the service has a consistent approach to least restrictive practice, de escalation, and personalised triggers and calming strategies. Confirm that staff know when to report suspected paradoxical reactions and that prescribers review promptly rather than continue the same plan.
9. Cognitive worsening, delirium, and reduced communication
What it looks like: New confusion, fluctuating attention, hallucinations, or reduced ability to communicate needs. In dementia, delirium can be missed, yet medicines can trigger or worsen it, especially with infections, dehydration, or pain.
Why it matters: Delirium is associated with increased mortality and functional decline. It also leads to poor experiences of care and increased use of restrictive interventions if not recognised.
MyQA audit checks:
Check whether delirium risk is recognised in care planning and whether staff have guidance on baseline cognition versus acute change. Audit pain assessment tools suitable for dementia and whether pain is reviewed before psychotropic escalation. Confirm infection screening pathways and hydration monitoring. Review whether mental capacity assessments are decision specific and updated when cognition changes, and whether communication support is used to maximise involvement, such as hearing aids, glasses, and accessible information.
10. Aspiration, pneumonia risk, and swallowing problems
What it looks like: Coughing during meals, wet voice, recurrent chest infections, increased secretions, reduced swallow coordination, and drowsiness during eating. Sedation and movement effects can contribute, as can dry mouth.
Why it matters: Aspiration pneumonia is a major cause of hospital admission and death in dementia. It is also strongly linked to positioning, feeding support, and timely SLT input.
MyQA audit checks:
Check whether swallowing risk assessments are completed and reviewed after psychotropic changes. Confirm dining support plans include posture, pacing, supervision level, and texture modification when recommended. Audit referrals to speech and language therapy and whether guidance is implemented consistently across staff. Cross check antibiotic use and chest infection episodes against sedation levels and PRN administration. Ensure oral care plans are robust, because oral hygiene reduces pneumonia risk.
Cross cutting MyQA audit themes that should sit behind all 10 checks
Legal and ethical governance: Evidence of consent, or Mental Capacity Act assessments and best interests decisions, including family and advocate involvement where appropriate. Clear recording of least restrictive options and why medication is required.
Indication and review: Each psychotropic has a documented indication, target symptoms, start date, intended duration, and review date. There is evidence of deprescribing attempts where appropriate and timely specialist input for complex cases.
PRN controls: PRN protocols include maximum dose, minimum interval, triggers, exclusions, and monitoring after administration. Records show what alternatives were tried first and whether PRN use triggers a prescriber review.
Non pharmacological approaches: Person centred behaviour support plans are present, specific, and used in practice. Staff can describe the person’s triggers, life history, preferences, and de escalation strategies.
Medicines administration safety: MARs are accurate, allergies recorded, covert administration is properly authorised where applicable, and there is clear auditing of errors and near misses with learning shared.
Communication and escalation: Staff know what to observe, how to record it, and when to escalate to the nurse, GP, pharmacist, or emergency services. Handover quality supports continuity and reduces missed warning signs.
How to use this article in a MyQA style care home audit
Sample a small cohort of residents prescribed antipsychotics, benzodiazepines, hypnotics, or sedating antidepressants. For each person, trace the story from assessment to prescribing rationale, consent and capacity, care planning, PRN governance, monitoring of the 10 effects above, incidents, and review outcomes. Then triangulate with staff interviews, observation of practice at medication rounds and mealtimes, and checks of training and policy compliance. This approach identifies not only whether records exist, but whether the home can evidence safe, effective, caring, responsive, and well led practice aligned to CQC expectations.
Disclaimer: This content is for quality assurance and governance support. It does not replace individual clinical judgement or prescribing advice.